镓-68-PSMA-11 PET在挽救性淋巴结清扫术前检测前列腺癌淋巴结转移中的表现:系统评价与荟萃分析
本系统评价与荟萃分析纳入14项研究共462例患者,评估镓-68-PSMA-11 PET在挽救性淋巴结清扫术前检测前列腺癌淋巴结转移的诊断性能。基于病灶分析和基于区域分析汇集的灵敏度分别为0.84和0.82,特异度分别为0.97和0.95,诊断比值比分别为189和82。作者结论认为PSMA-PET可识别可能从挽救性淋巴结清扫中获益的患者,并可能指导基于病灶或区域的清扫。
要点
- 基于病灶分析汇集灵敏度0.84(95%CI 0.61-0.95),特异度0.97(95%CI 0.95-0.99)。
- 基于区域分析汇集灵敏度0.82(95%CI 0.72-0.89),特异度0.95(95%CI 0.70-0.99)。
- 作者认为PSMA-PET可识别可能从挽救性淋巴结清扫中获益的患者。
核心结论
- 作者结论认为,PSMA-PET在挽救性淋巴结清扫术前检测生化复发患者淋巴结病变具有高准确性和临床相关的高阳性与阴性预测值。
- 作者认为PSMA-PET可识别可能从挽救性淋巴结清扫中获益的患者,并可能指导基于病灶或区域的清扫。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、SCOPUS、Web of Science和Cochrane Library(2018年11月11日),纳入14项研究共462例患者。
- 纳入标准为在生化复发前列腺癌患者中评估挽救性淋巴结清扫术前PSMA-PET诊断性能,并报告基于病灶和/或基于区域分析的真阳性、假阳性、假阴性和真阴性数以与组织病理学比较。
主要发现
- 基于患者分析的PSMA-PET阳性预测值范围为0.70至0.93。
- 基于病灶分析汇集灵敏度0.84(95%CI 0.61-0.95),基于区域分析汇集灵敏度0.82(95%CI 0.72-0.89)。
- 基于病灶分析汇集特异度0.97(95%CI 0.95-0.99),基于区域分析汇集特异度0.95(95%CI 0.70-0.99)。
- 基于病灶分析诊断比值比189(95%CI 39-920),基于区域分析诊断比值比82(95%CI 8-832)。
临床怎么用
- 作者认为PSMA-PET可识别可能从挽救性淋巴结清扫中获益的患者,并可能指导基于病灶或区域的清扫。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Salvage lymph node dissection (sLND) for nodal recurrence in prostate cancer (PCa) patients with biochemical recurrence (BCR) is still not recommended in current guidelines, because of the diagnostic inaccuracy of current conventional imaging. To assess the performance of [68Ga] Ga-prostate-specific membrane antigen conjugate 11 positron emission tomography (PSMA-PET) in detecting PCa lymph node metastasis using pathologic confirmation through sLND. METHODS: Literature search was conducted using the MEDLINE, SCOPUS, Web of Science, and Cochrane Library on November 11th, 2018 to identify the eligible studies. Studies were eligible if they investigated the diagnostic performance of PSMA-PET before sLND in PCa patients with BCR and reported the number of true positive, false positive, false negative, and true negative on a lesion-based and/or field-based analyses to compare with histopathologic findings in sLND specimens. RESULTS: Fourteen studies published between 2015 and 2018 comprising 462 patients were selected in this systematic review and meta-analysis. The positive predictive value of PSMA-PET before sLND on a patient-based analysis ranged between 0.70 and 0.93. The pooled sensitivity using lesion-based and field-based analyses were 0.84 (95%CI: 0.61-0.95) and 0.82 (95%CI: 0.72-0.89), respectively. The pooled specificity using lesion-based and field-based analyses were 0.97 (95%CI: 0.95-0.99) and 0.95 (95%CI: 0.70-0.99), respectively. The diagnostic odds ratio using lesion-based and field-based analyses were 189 (95%CI: 39-920) and 82 (95%CI: 8-832), respectively. CONCLUSIONS: PSMA-PET before sLND provided highly accurate performance with clinically relevant high positive and negative predictive values for detecting lymph node disease in patients with BCR after local treatment with curative intent for PCa. PSMA-PET can identify the patients who are likely to benefit from sLND and possibly direct to lesion or region-based dissection.
引用
- Kimura S, Abufaraj M, Janisch F, et al. Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2019. PMID: 31147628. doi:10.1038/s41391-019-0156-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。